Lesson · 40 min · Free
Drug Metabolism: Phase I Reactions
Drug Metabolism: Phase I Reactions body { font-family: sans-serif; line-height: 1.6; margin: 20px; } h1, h2 { color: #2c3e50; } pre { background-color: #ecf0f1; padding: 15px; border-left: 5px solid #3498db; overflow-x:
Drug Metabolism: Phase I Reactions
Welcome to the "Pharmacokinetics & Drug Metabolism" course! In this lesson, we will delve into the fascinating world of drug metabolism, specifically focusing on Phase I reactions. Drug metabolism is a critical process in pharmacokinetics, influencing a drug's efficacy, duration of action, and potential for toxicity. It primarily occurs in the liver, but other tissues like the intestines, kidneys, and lungs also contribute significantly. The body's primary goal in drug metabolism is to convert lipophilic (fat-soluble) drugs into more hydrophilic (water-soluble) metabolites. This transformation facilitates their excretion, mainly via the kidneys. Without this metabolic conversion, many lipophilic drugs would remain in the body for extended periods, leading to prolonged pharmacological effects and potential accumulation to toxic levels.
Phase I Reactions: Introduction to Functionalization
Phase I reactions are often referred to as "functionalization reactions." Their main objective is to introduce or expose a polar functional group (e.g., -OH, -NH2, -SH, -COOH) on the drug molecule. This modification either makes the drug more polar directly, allowing for easier excretion, or creates a suitable site for subsequent Phase II (conjugation) reactions. While Phase I reactions typically decrease pharmacological activity, it's important to note that some drugs are activated by these reactions (prodrugs), and others can be converted into active or even toxic metabolites. The most common and important class of enzymes involved in Phase I metabolism are the Cytochrome P450 (CYP) enzymes. These are a superfamily of heme-containing monooxygenases found predominantly in the endoplasmic reticulum of hepatocytes. CYPs catalyze a wide variety of oxidative reactions, including hydroxylations, dealkylations, epoxidations, and N-oxidations. Other non-CYP enzymes, such as flavin-containing monooxygenases (FMOs), alcohol dehydrogenases, aldehyde dehydrogenases, esterases, and reductases, also play significant roles in Phase I metabolism.
Key Types of Phase I Reactions:
Let's explore some of the most common types of Phase I reactions in more detail: Oxidation: This is the most prevalent type of Phase I reaction, primarily catalyzed by CYP enzymes. It involves the addition of oxygen or removal of hydrogen from the drug molecule. Hydroxylation: Addition of a hydroxyl (-OH) group. E.g., hydroxylation of phenytoin. N-dealkylation: Removal of an alkyl group from a nitrogen atom. E.g., conversion of codeine to morphine. O-dealkylation: Removal of an alkyl group from an oxygen atom. E.g., conversion of codeine to morphine (minor pathway). S-dealkylation: Removal of an alkyl group from a sulfur atom. Oxidative deamination: Removal of an amino group. N-oxidation, S-oxidation: Addition of oxygen to nitrogen or sulfur atoms. Reduction: Less common than oxidation, but still significant. These reactions involve the gain of electrons or hydrogen, or the loss of oxygen. Nitro and azo compounds are often metabolized via reduction. E.g., reduction of chloramphenicol. Hydrolysis: Involves the cleavage of a chemical bond by the addition of water. Esterases and amidases are key enzymes in these reactions. E.g., hydrolysis of aspirin (an ester) to salicylic acid and acetic acid. The following example illustrates a common CYP-mediated hydroxylation reaction: Drug-H + O2 + NADPH + H+ ---(CYP450)---> Drug-OH + H2O + NADP+ Here, a hydrogen atom on the drug molecule is replaced by a hydroxyl group, making the molecule more polar. Another example, demonstrating N-dealkylation: R-NH-CH3 ---(CYP450, oxidative dealkylation)---> R-NH2 + HCHO (formaldehyde) This reaction removes a methyl group from a secondary amine, producing a primary amine and formaldehyde. Understanding the specific CYP isoforms involved in a drug's metabolism is crucial in pharmacotherapy. For instance, CYP3A4 is the most abundant CYP enzyme in the human liver and intestine, metabolizing approximately 50% of all clinically used drugs. Genetic polymorphisms in CYP enzymes (e.g., CYP2D6, CYP2C9, CYP2C19) can lead to significant inter-individual variability in drug response, classifying individuals as poor metabolizers, extensive metabolizers, or ultra-rapid metabolizers. This variability has profound implications for drug dosing and efficacy.
Key Takeaways:
Phase I reactions introduce or expose polar functional groups on drug molecules. The primary goal is to increase water solubility for excretion. Cytochrome P450 (CYP) enzymes are the most important class of enzymes for Phase I oxidation reactions. Other enzymes like FMOs, esterases, and reductases also participate. Common Phase I reactions include oxidation (hydroxylation, dealkylation), reduction, and hydrolysis. Phase I metabolism can lead to activation, inactivation, or formation of toxic metabolites. Genetic polymorphisms in CYP enzymes contribute to inter-individual variability in drug response.
Practice Exercise:
Consider a novel drug candidate, 'X', which is highly lipophilic and primarily eliminated unchanged in the feces. To improve its pharmacokinetic profile and facilitate renal excretion, medicinal chemists aim to introduce a hydroxyl group into its structure. Which class of enzymes would most likely be targeted to achieve this functionalization in vivo, and what specific type of Phase I reaction would be involved? Briefly explain the significance of this modification for drug excretion.
Watch the full lesson — free
This topic is part of Pharmacokinetics & Drug Metabolism, a complete AI-narrated video course. Press play once and watch the entire lecture like a movie.
Start the course free →